Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thromboembolic stroke

Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 1987 67 394-398. [Pg.56]

Barnwell SL, Clark WM, Nguyen TT, O Neill OR, Wynn ML, Coull BM. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. Am J Neuroradiol 1994 15 1817-1822. [Pg.91]

Risks of OC use The use of OCs is associated with increased risk of thromboembolism, stroke. Ml, hypertension, hepatic neoplasia, and gallbladder disease, although risk of serious morbidity or mortality is very small in healthy... [Pg.214]

Nimodipine, a member of the dihydropyridine group of calcium channel blockers, has a high affinity for cerebral blood vessels and appears to reduce morbidity after a subarachnoid hemorrhage. Nimodipine was approved for use in patients who have had a hemorrhagic stroke, but it has recently been withdrawn. Nicardipine has similar effects and is used by intravenous and intracerebral arterial infusion to prevent cerebral vasospasm associated with stroke. Verapamil as well, despite its lack of vasoselectivity, is used by the intra-arterial route in stroke. Some evidence suggests that calcium channel blockers may also reduce cerebral damage after thromboembolic stroke. [Pg.262]

Abbott, R. D., Curb, J. D., Rodriguez, B. L., Sharp, D. S., Burchfiel, C. M., and Yano, K. (1996). Effect of dietary calcium and milk consumption on risk of thromboembolic stroke in older middle-aged men. The Honolulu Heart Program. Stroke 27, 813-818. [Pg.33]

Busch E, Kruger K, Hossmann K-A (1997) Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 778 16-24... [Pg.68]

De Crespigny AJ, Tsuura M, Moseley ME, Kucharczyk J (1993) Perfusion and diffusion MR imaging of thromboembolic stroke. J Magn Reson Imaging 3 746-754... [Pg.68]

Nicotera P (2003) Molecular switches deciding the death of injured neurons. Toxicol Sci 74 4-9 Niessen F, Hilger T, Hoehn M, Hossmann KA (2003) Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34 2019-2024 NINDS rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 1581-1587... [Pg.71]

Schuler OG, Eriskat J, Baethmann AJ, Back T (2001a) Thrombolysis induces a reperfusion-dependent inhibition of peri-infarct depolarizations in experimental thromboembolic stroke. J Cereb Blood Flow Metab 21 S396 Schuler OG, Plesnila N, Otto D, Baethmann AJ, Back T (2001b) Early thrombolysis inhibits periinfarct depolarizations in embolic MCA occlusion. NeuroReport 12 3943-3946 Schwindt W, Burke M, Pillekamp F, Luhmann HJ, Hoehn M (2004) Functional magnetic resonance imaging and somatosensory evoked potentials in rats with a neonatally induced freeze lesion of the somatosensory cortex. J Cereb Blood FlowMetab 24 1409-1418... [Pg.72]

Lapchak PA, Chapman DF, Zivin JA (2000) Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31 3034-3040... [Pg.161]

Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 l(8649) 1215-20. [Pg.3427]

Curb J D, Abbott RD, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003 107 2016-20. [Pg.970]

Therapy Effect. The effect of thrombolytic therapy on metabolic changes was studied in rat brains submitted to thromboembolic stroke by a MRSI. Temporal changes in the cerebral methabolites lactate and N-acetylaspartate (NAA) were determined. In individual pixels, the probability of metabolic tissue recovery clearly declined with increasing lactate concentration before thrombolysis. [Pg.451]

In a worldwide survey of AF ablation, major complications were reported in 6% of patients, including cardiac tamponade in 1.2%, stroke in 0.28% and transient ischemic attacks in 0.66% of left sided procedures (164). Periprocedural mortality was reported in 0.05%, Most thromboembolic strokes occur within two weeks of the ablation procedure (165). To reduce the risk of stroke, anticoagulation is often instituted prior to ablation, particularly in patients with CHADS-II risk factors (congestive heart failure or left ventricular dysfunction, hypertension,... [Pg.113]

Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M (1998) PROACT a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke 29 4-11. [Pg.79]

Yang Y, Li Q, Yang T, Hussain M, Shuaib A (2003) Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CPIOI, 606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J Neurosurg 98 397-403... [Pg.106]

Atrial fibrillation (Afib) is the most common cardiac arrhythmia in the United States. Persons with Afib are at increased risk of blood clots in the heart that in turn may lead to thromboembolic stroke. The medication warfarin is often prescribed as a preventative measure. While the effectiveness of warfarin in the prevention of thromboembolic stroke is well established, its physiological mechanism of action also puts users at higher risk for other adverse events, for example, bleeding, whose health consequences may be just as devastating. Randomized clinical trials of warfarin have reported favorable results in both effectiveness and safety analyses. However, some clinicians have expressed doubt as to whether these results validly represent the situation in the general Afib patient population. The reason is that typical Afib patients tend to have more comorbidities and may not be as healthy as trial participants. [Pg.185]

Cardiac valves with components fabricated from low temperature isotropic carbons (pyrolytic carbon) are successfully used clinically [23]. These materials are appropriate for such applications as mechanical valves which require long-term chemical inertness, smoothness, and wear-resistance. The reasons for the marked improvement in the performance (reduced thrombosis and thromboembolic stroke rates) of these newer vs. older style heart valves are not entirely understood, but are undoubtedly multifactorial and related to improved patient management and valve design, as well as to the nature of the carbon surface. The specific benefits conferred by pyrolytic carbons with respect to blood cell and protein interactions, resulting in a very low frequency of clinical complications, remain to be defined. The use of carbon coatings has been proposed for other devices, i.e., vascular grafts, although such devices have not yet been used clinically. [Pg.550]

The effects of 16-, 17-, 18-, 19-, and 20-HETE have been studied to varying degrees. Activated polymorphonuclear leukocytes (PMNs) are known to produce 16-HETE. In vitro, 16(7 )-HETE inhibits human PMN adhesion and aggregation. Administration of 16-HETE to rabbits with thromboembolic stroke leads to reduction in intracranial pressure [59]. Synthesis of leukot-liene B4, a pro-inflammatory molecule, is also increased by 16(7 )-HETE. Carroll et al. demonstrated that 16(7 )-HETE promotes vasodilation of renal arteries in a COX-dependent manner [60], Furthermore, 16(5)-HETE inhibits the activity of the adenosine triphosphatase (ATPase) in the renal proximal tubule [60], Similarly, 17(iS)-HETE inhibits proximal tubule ATPase activity while 17(i )-HETE is inactive in this system. [Pg.886]

Bednar MM, Gross CE, Russell SR, Fuller SP, Ahem TP, Howard DB, Falck JR, Reddy KM, Balazy M (2000) 16(/ )-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery 47 1410-1418. Discussion 1418-1419... [Pg.897]

Reduction in the incidence of atrial fibrillation consequent to atrial pacing could plausibly decrease the incidence of thromboembolic stroke. However, as discussed above, the reduction in atrial fibrillation is relatively small and in the elderly pacemaker population, atrial fibrillation is only one of several causes of stroke. Additionally, the high use of anticoagulation in pacemaker patients (72% in the MOST study (50)) may substantially reduce the magnitude of benefit of prevention of atrial fibrillation with atrial-based pacing. [Pg.393]

RED FLAG Untreated atrial fibrillation can lead to cardio-vascular collapse, thrombus formation, pulmonary embolism, and thromboembolic stroke. [Pg.73]


See other pages where Thromboembolic stroke is mentioned: [Pg.92]    [Pg.127]    [Pg.279]    [Pg.10]    [Pg.60]    [Pg.69]    [Pg.265]    [Pg.582]    [Pg.399]    [Pg.241]    [Pg.288]    [Pg.186]    [Pg.272]    [Pg.386]    [Pg.393]    [Pg.1143]    [Pg.272]    [Pg.273]   
See also in sourсe #XX -- [ Pg.393 ]




SEARCH



Thromboembolism

© 2024 chempedia.info